| Objective To investigate the effect of insulin glargine combined with Sitagliptin on blood glucose fluctuation, inflammatory factors and hypoglycemic events in first-visit type 2 diabetes(T2DM). Methods A total of 124 cases of T2DM patients treated in Wuxi NO.3 People's Hospital from June 2017 to October 2018 were selected as the study subjects and were randomly divided into control group and observation group with 62 cases in each group.The control group was treated with insulin glargine combined with repaglinide, while the observation group with insulin glargine combined with Sitagliptin. The following indexes of the two groups were compared:fasting blood glucose (FBG), 2 hours postprandial blood glucose (2 hPBG), glycosylated hemoglobin (HbA1c), (mean amplitude of glycemic excursion (MAGE), effective blood glucose fluctuations in frequency (NGE), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), C-reactive protein (CRP), body mass index (BMI), incidence of hypoglycemia, dosage of insulin glargine. Results The MAGE and NGE in observation group were lower than those in control group, and the difference was statistically significant (P<0.05). The serum CRP, TNF-α, IL-6 in observation group were lower than those in control group, and the difference was statistically significant (P<0.05). BMI of observation group was (23.24±2.83) kg/m2, which was lower than that of control group, and the difference was statistically significant (P<0.05). The incidence of hypoglycemia (1.60%) and the dosage of insulin glargine (25.54±5.09) U/d in observation group were significantly lower than those in control group (P<0.05). Conclusions Insulin glargine combined with Sitagliptin can reduce blood sugar fluctuation,reduce microinflammation, and decrease the incidence of hypoglycemia and insulin glargine dosage. |
